IBDEI029 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,505,1,4,0)
 ;;=4^C79.72
 ;;^UTILITY(U,$J,358.3,505,2)
 ;;=^5001357
 ;;^UTILITY(U,$J,358.3,506,0)
 ;;=C48.2^^2^23^22
 ;;^UTILITY(U,$J,358.3,506,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,506,1,3,0)
 ;;=3^Malignant neoplasm of peritoneum, unspecified
 ;;^UTILITY(U,$J,358.3,506,1,4,0)
 ;;=4^C48.2
 ;;^UTILITY(U,$J,358.3,506,2)
 ;;=^5001122
 ;;^UTILITY(U,$J,358.3,507,0)
 ;;=C45.0^^2^23^28
 ;;^UTILITY(U,$J,358.3,507,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,507,1,3,0)
 ;;=3^Mesothelioma of pleura
 ;;^UTILITY(U,$J,358.3,507,1,4,0)
 ;;=4^C45.0
 ;;^UTILITY(U,$J,358.3,507,2)
 ;;=^5001095
 ;;^UTILITY(U,$J,358.3,508,0)
 ;;=C38.4^^2^23^23
 ;;^UTILITY(U,$J,358.3,508,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,508,1,3,0)
 ;;=3^Malignant neoplasm of pleura
 ;;^UTILITY(U,$J,358.3,508,1,4,0)
 ;;=4^C38.4
 ;;^UTILITY(U,$J,358.3,508,2)
 ;;=^267140
 ;;^UTILITY(U,$J,358.3,509,0)
 ;;=C41.9^^2^23^14
 ;;^UTILITY(U,$J,358.3,509,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,509,1,3,0)
 ;;=3^Malignant neoplasm of bone and articular cartilage, unsp
 ;;^UTILITY(U,$J,358.3,509,1,4,0)
 ;;=4^C41.9
 ;;^UTILITY(U,$J,358.3,509,2)
 ;;=^5000993
 ;;^UTILITY(U,$J,358.3,510,0)
 ;;=C49.9^^2^23^17
 ;;^UTILITY(U,$J,358.3,510,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,510,1,3,0)
 ;;=3^Malignant neoplasm of connective and soft tissue, unsp
 ;;^UTILITY(U,$J,358.3,510,1,4,0)
 ;;=4^C49.9
 ;;^UTILITY(U,$J,358.3,510,2)
 ;;=^5001136
 ;;^UTILITY(U,$J,358.3,511,0)
 ;;=C47.9^^2^23^12
 ;;^UTILITY(U,$J,358.3,511,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,511,1,3,0)
 ;;=3^Malig neoplasm of prph nerves and autonm nervous sys, unsp
 ;;^UTILITY(U,$J,358.3,511,1,4,0)
 ;;=4^C47.9
 ;;^UTILITY(U,$J,358.3,511,2)
 ;;=^5001121
 ;;^UTILITY(U,$J,358.3,512,0)
 ;;=C43.9^^2^23^13
 ;;^UTILITY(U,$J,358.3,512,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,512,1,3,0)
 ;;=3^Malignant melanoma of skin, unspecified
 ;;^UTILITY(U,$J,358.3,512,1,4,0)
 ;;=4^C43.9
 ;;^UTILITY(U,$J,358.3,512,2)
 ;;=^5001015
 ;;^UTILITY(U,$J,358.3,513,0)
 ;;=D03.9^^2^23^27
 ;;^UTILITY(U,$J,358.3,513,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,513,1,3,0)
 ;;=3^Melanoma in situ, unspecified
 ;;^UTILITY(U,$J,358.3,513,1,4,0)
 ;;=4^D03.9
 ;;^UTILITY(U,$J,358.3,513,2)
 ;;=^5001908
 ;;^UTILITY(U,$J,358.3,514,0)
 ;;=C44.01^^2^23^3
 ;;^UTILITY(U,$J,358.3,514,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,514,1,3,0)
 ;;=3^Basal cell carcinoma of skin of lip
 ;;^UTILITY(U,$J,358.3,514,1,4,0)
 ;;=4^C44.01
 ;;^UTILITY(U,$J,358.3,514,2)
 ;;=^340464
 ;;^UTILITY(U,$J,358.3,515,0)
 ;;=C44.02^^2^23^31
 ;;^UTILITY(U,$J,358.3,515,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,515,1,3,0)
 ;;=3^Squamous cell carcinoma of skin of lip
 ;;^UTILITY(U,$J,358.3,515,1,4,0)
 ;;=4^C44.02
 ;;^UTILITY(U,$J,358.3,515,2)
 ;;=^340465
 ;;^UTILITY(U,$J,358.3,516,0)
 ;;=C44.111^^2^23^10
 ;;^UTILITY(U,$J,358.3,516,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,516,1,3,0)
 ;;=3^Basal cell carcinoma skin/ unsp eyelid, including canthus
 ;;^UTILITY(U,$J,358.3,516,1,4,0)
 ;;=4^C44.111
 ;;^UTILITY(U,$J,358.3,516,2)
 ;;=^5001019
 ;;^UTILITY(U,$J,358.3,517,0)
 ;;=C44.121^^2^23^38
 ;;^UTILITY(U,$J,358.3,517,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,517,1,3,0)
 ;;=3^Squamous cell carcinoma skin/ unsp eyelid, including canthus
 ;;^UTILITY(U,$J,358.3,517,1,4,0)
 ;;=4^C44.121
 ;;^UTILITY(U,$J,358.3,517,2)
 ;;=^5001022
 ;;^UTILITY(U,$J,358.3,518,0)
 ;;=C44.211^^2^23^9
 ;;^UTILITY(U,$J,358.3,518,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,518,1,3,0)
 ;;=3^Basal cell carcinoma skin/ unsp ear and external auric canal
 ;;
 ;;$END ROU IBDEI029
